FDA approves first long-acting recombinant coagulation Factor IX...

The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX , Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

http://ift.tt/1gLzPaN